Rationale: Pulmonary arterial hypertension (PAH) is characterized in part by increased dead space ventilation, which can be estimated noninvasively at the bedside by measurement of end-tidal CO 2 (ETCO 2 ).
Pulmonary arterial hypertension (PAH) is a highly morbid disease, though modern registry data suggest that some patients may have a more favorable survival than historical control subjects (1, 2) . Noninvasive tools that are available at the bedside are needed to identify patients at high risk of death because currently available prognostic metrics such as right heart catheterization, brain natriuretic peptide, and echocardiography are costly, time consuming, and not always readily available.
PAH is a disease of vascular obstruction resulting in increased dead space secondary to obstruction of pulmonary arterioles, leading to alveoli that are ventilated but not perfused. The PCO 2 in normal, perfused alveoli approximates central venous PCO 2 (on average, about 40 mm Hg). In alveoli that are ventilated but not perfused (i.e., dead space), the PCO 2 is near 0 mm Hg.
As dead space increases, the end-tidal CO 2 (ETCO 2 ) decreases as air from both perfused and unperfused alveoli mix in the large airways upon exhalation.
Prior publications by our group and others have shown that ETCO 2 is reduced in PAH (2, 3) compared with control subjects and patients with pulmonary venous hypertension (World Health Organization [WHO] class II PAH). As the fraction of pulmonary arterial obstruction increases in advancing PAH, ETCO 2 should fall proportionally. Thus, the degree of ETCO 2 suppression may be a surrogate for the extent of pulmonary vascular disease and therefore may have prognostic value. Further, our prior data suggested that with new initiation of intravenous epoprostenol, ETCO 2 increased; however, it is unknown if ETCO 2 is unchanged over time in a cohort of patients largely on stable therapy.
We hypothesized that ETCO 2 is stable over time in PAH and that lower ETCO 2 is associated with higher mortality. We tested this hypothesis in a cohort of patients with PAH with ETCO 2 measurements who were followed prospectively at the Vanderbilt University Center for Pulmonary Vascular Disease. These data were partially presented previously in abstract form (4) .
Methods

Study Design
We conducted a single-center, prospective study of ETCO 2 in patients with PAH. The Vanderbilt University Medical Center Institutional Review Board (Nashville, TN) approved the study, and all subjects gave informed consent (IRB 070270). Previous results of this work have been published, but the analyses presented here have not been reported previously (2).
Setting and Population
All patients over the age of 18 years with pulmonary hypertension seen at the Vanderbilt University Center for Pulmonary Vascular Disease clinic were offered enrollment between September 2009 and February 2010 (2) . Patients who presented for a return visit during that time frame had ETCO 2 measurement repeated.
Patients were evaluated according to standard criteria to identify WHO classes I-V PAH. This analysis included only patients with group 1 PAH. PAH was defined as previously described (2) by physicians experienced in pulmonary hypertension evaluation (I.M.R., A.R.H.) and further required right heart catheterization with a mean pulmonary arterial pressure greater than or equal to 25 mm Hg and a pulmonary capillary wedge pressure less than or equal to 15 mm Hg (5).
Measurements ETCO 2 was measured using the Nellcor NPB-75 handheld capnograph (Nellcor Puritan Bennett/Covidien, Boulder, CO) (6) . Trained testers who were blinded to diagnosis obtained the ETCO 2 measurement. Five ETCO 2 measurements were recorded after the patient rested for at least 5 minutes prior to the 6-minute walk test, as previously described (2) . The mean of these five measurements was used for analysis. Reproducibility and variability of ETCO 2 measurements using the Nellcor NPB-75 handheld capnograph have been described previously (2) . Six-minute walk tests were performed per the American Thoracic Society criteria (7).
Demographic data, including age, sex, body mass index (BMI), diagnosis, comorbidities (including diabetes mellitus, coronary artery disease, hypertension, and hyperlipidemia), New York Heart Association (NYHA) functional class, and 6-minute walk distance, were collected upon enrollment. Pulmonary function test data and right heart catheterization data were collected around the time of enrollment.
Follow-Up
Routine practice at the Center for Pulmonary Vascular Disease was initially and approximately annual right heart catheterization and 6-minute walk testing approximately every 3-6 months unless clinically indicated. When patients were seen within the enrollment window, ETCO 2 was remeasured. Patients who did not return for follow-up or did not have repeat 6-minute walk testing did not have repeat Definition of abbreviations: BMI = body mass index; CCB = calcium channel blocker; CHD = congenital heart disease; CTD = connective tissue disease; DL CO = diffusing capacity of the lung for carbon monoxide; ERA = endothelin receptor antagonist; HPAH = heritable pulmonary arterial hypertension; IPAH = idiopathic pulmonary arterial hypertension; NYHA = New York Heart Association; PAH = pulmonary arterial hypertension; PDE5 = phosphodiesterase type 5 inhibitor. Combination therapy included ERA 1 prostaglandin, PDE5 1 prostaglandin, ERA 1 PDE5 1 prostaglandin, CCB 1 PDE5, and CCB 1 ERA. Data are presented as mean 6 SD unless otherwise noted. *Alive (n = 44); dead (n = 24). † Alive (n = 43); dead (n = 24). ‡ Alive (n = 47); dead (n = 23). 
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Results
Study Population
A total of 84 patients with PAH were enrolled in the study. Diagnoses included idiopathic PAH (n = 33), heritable PAH (n = 6), connective tissue disease-associated PAH (n = 23), portopulmonary hypertension (n = 1), corrected or simple congenital heart disease-associated PAH (n = 15), and other PAH (n = 6). Two patients were lost to follow-up. The other 82 patients were followed for a median of 60 (interquartile range, 47-63) months. In total, 26 of 82 patients died during the follow-up period.
Demographic differences between those who died during follow-up and those who were still alive are shown in Table 1 . Patients who died were more likely to be older (58.5 6 14.9 vs. 47.6 6 12.2 yr; P , 0.05) and to have shorter 6-minute walk distances (296 6 127 vs. 401 6 92 m; P , 0.05). There was no significant difference between the number of men and women in the two groups, nor was there a difference in BMI or associated comorbidities. Patients who died were more likely than survivors to have heritable or connective tissue diseaseassociated PAH and less likely than survivors to have congenital heart diseaseassociated PAH. There was no significant difference in the PAH-directed treatments of the two groups. Patients who died during follow-up were more likely to be in NYHA functional class III or IV at baseline measurement than those who were still alive (P , 0.05). ETCO 2 was significantly higher in survivors than in those patients who died (30.5 6 4.8 vs. 27.1 6 4.2 mm Hg; P = 0.004) ( Figure 1 ). In patients with available pulmonary function test data (n = 71 [86.6%]), diffusing capacity of the lung for carbon monoxide (DL CO ) was significantly higher in survivors than in those who had died at follow-up, whereas there were no differences in percent predicted FEV 1 or FVC. ETCO 2 correlated weakly with DL CO (r 2 = 0.28; P = 0.0177) ( Figure 2 ). Right heart catheterization data were available for 81 patients (Table 2) . Median time between ETCO 2 measurement and cardiac catheterization was 7 (interquartile range, 3-21) months. Mean right atrial pressures, pulmonary arterial systolic pressures, mean pulmonary arterial pressures, pulmonary capillary wedge pressures, pulmonary vascular resistance, and Fick cardiac indices were not significantly different between patients who were alive or dead at follow-up (P . 0.05 for all).
To test the stability of ETCO 2 measurement over time, we examined patients with at least two measurements over the course of the study. There were 52 patients with more than one measurement a median of 17 months 
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apart. In this cohort, ETCO 2 was unchanged (29.4 6 5.0 vs. 28.4 6 5.2 mm Hg; P = 0.25), including when analyzed separately by vital status. The change in ETCO 2 between enrollment and follow-up measurements was not significantly different between patients receiving oral therapy versus those patients receiving prostaglandins (either alone or in combination with oral therapy) at the time of enrollment in this study (n = 50; P = 0.80).
To determine if there was a difference in survival between patients with low ETCO 2 and those with preserved ETCO 2 , we separated the entire cohort according to the median ETCO 2 of 29 mm Hg. We found that there was no significant difference in age, sex, presence of comorbidities (hypertension, hyperlipidemia, coronary artery disease, or diabetes mellitus), 6-minute walk distance, types of PAH, or therapies received between the two groups (Table 3) . BMI was significantly higher in patients with ETCO 2 greater than 29 mm Hg (P = 0.04). Despite relatively similar demographics, there were differences in hemodynamics. Specifically, pulmonary capillary wedge pressure was higher and pulmonary vascular resistance was lower in the patients with higher ETCO 2 readings (P , 0.05) ( Table 4) . Mean right atrial pressures, pulmonary artery systolic pressures, mean pulmonary arterial pressures, and Fick cardiac indices were not significantly different between the two groups (P . 0.05 for all). After stratification by median ETCO 2 of 29 mm Hg, survival in each group was analyzed with a KaplanMeier curve (Figure 3) . Patients with lower ETCO 2 had a median survival of 58 months as compared with 61 months in patients with higher ETCO 2 (P = 0.006).
Kaplan-Meier curves stratified by upper and lower median ETCO 2 are shown in We were limited in the number of covariates for which we could adjust without overfitting the model, because only 26 deaths occurred during follow-up in our cohort. Therefore, adjustment for additional covariates was exploratory. After adjustment for age, sex, and DL CO , the relationship between ETCO 2 and survival was no longer significant (HR, 0.91; 95% CI, 0.82-1.01; P = 0.085). When adjusting for age, sex, and 6-minute walk distance, we found that the association between ETCO 2 and survival trended toward statistical significance (HR, 0.91; 95% CI, 0.83-1.00; P = 0.06). However, after adjusting for age, sex, and serum bicarbonate levels as a surrogate for acid-base status, we observed that the association between ETCO 2 and survival persisted (HR, 0.88; 95% CI, 0.79-0.98; P = 0.017).
To determine what was different between those patients who had improvement in their ETCO 2 and those who had a decrease in their ETCO 2 , the cohort was separated into three groups on the basis of a mean ETCO 2 change of 21 mm Hg with Definition of abbreviations: BMI = body mass index; CCB = calcium channel blocker; CHD = congenital heart disease; CTD = connective tissue disease; ERA = endothelin receptor antagonist; ETCO 2 = end-tidal carbon dioxide pressure; HPAH = heritable pulmonary arterial hypertension; IPAH = idiopathic pulmonary arterial hypertension; NYHA = New York Heart Association; PAH = pulmonary arterial hypertension; PDE5 = phosphodiesterase type 5 inhibitor. Data are presented as mean 6 SD unless otherwise noted. Combination therapy included ERA 1 prostaglandin, PDE5 1 prostaglandin, ERA 1 PDE5 1 prostaglandin, CCB 1 PDE5, and CCB 1 ERA. 
an SD of 5.5 mm Hg: patients who had an increase in ETCO 2 by at least 5 mm Hg, patients who had a decrease in ETCO 2 by at least 5 mm Hg, and patients who had an increase or decrease in ETCO 2 by less than 5 mm Hg. There was no significant difference in the demographics of these groups, including age, sex, BMI, and comorbidities ( Table 5 ). The numbers were too small to compare types of PAH and therapies (Table 5 ). There were also no significant differences in the pulmonary function test data and right heart catheterization data that were analyzed among the three groups (Table 5) . We also compared ETCO 2 measurements among NYHA functional classes at enrollment and noted no significant difference in ETCO 2 between groups ( Figure 4 ). (Note that, for analysis, the NYHA functional classes III and IV were grouped together because only one patient was classified as NYHA functional class IV.)
Discussion
In this study, we have shown that ETCO 2 , a safe, simple, and inexpensive measurement, is stable over time and that lower values are associated with increased mortality in patients with PAH. We also showed that DL CO correlates with ETCO 2 , suggesting potentially similar insight into the degree of pulmonary vascular obstruction in patients with PAH. Our data suggest that this readily available bedside test may be a physiologically relevant marker of poor prognosis in PAH.
Identifying patients with PAH at high risk of mortality has proved to be challenging. Many of the tests used to determine the severity of the disease are expensive, invasive, and time consuming (i.e., right heart catheterization or echocardiography). Some metrics are available at the bedside, including important demographic predictors such as age, sex, 6-minute walk distance, and type of PAH, but these give limited insight into the severity of pulmonary vascular obstruction. Measuring ETCO 2 is an inexpensive, noninvasive, quick test that can be performed at the bedside and, on the basis of our data, may offer valuable information regarding disease severity. Consistent with prior publications, older patients and those with shorter 6-minute walk distances and higher NYHA functional classes had worse outcomes in our sample (1, 8) . After controlling for age, we found that ETCO 2 remained an independent predictor of increased mortality, and after adjustment for 6-minute walk distance, there was a strong trend toward persistent significance, suggesting that ETCO 2 may offer information additional to that of these more traditional, readily available metrics. Further, in patients who cannot perform 6-minute walk testing, ETCO 2 may be a useful prognostic tool.
Our prior work demonstrated that ETCO 2 correlated with pulmonary vascular resistance and cardiac index at enrollment, traditional hemodynamic markers of PAH severity, and we now show the role that ETCO 2 may have in identifying high-risk patients with PAH (2) . We have previously demonstrated that ETCO 2 increases after initiation of therapy with intravenous prostaglandins in a small cohort of patients. In this larger cohort treated chronically with oral and prostaglandin therapies, we found that ETCO 2 was stable over time. The difference likely reflects the new start of intravenous epoprostenol reported in the prior publication and, perhaps, reduced capacity of oral therapies to improve cardiac output, a known determinant of ETCO 2 (9, 10) .
COPD, left ventricular failure, and PAH are all characterized by _ V/ _ Q mismatch, increased dead space, and decreased ETCO 2 (11) . The effect of interstitial lung disease on ETCO 2 is unknown. Prior studies have demonstrated a correlation between lower ETCO 2 and the severity of cardiac disease and have also demonstrated that lower ETCO 2 in this population correlates with higher New York Heart Association functional class ORIGINAL RESEARCH (12) . ETCO 2 has been studied in both chronic heart failure and PAH in relation to exercise (11, 13) . In severe chronic heart failure and PAH, ETCO 2 decreases during exercise (11, 13) . That research group attributed declining ETCO 2 in the setting of increasing exercise to an inability to increase pulmonary perfusion (11) . Prior to these data, the relationship between ETCO 2 and survival was not studied.
DL CO measures the ability of a gas to transfer from the alveoli to red blood cells in the pulmonary capillaries. Because alveoli that are affected by dead space ventilation have no blood flow, they are unlikely to participate in absorbing gas into the alveolar capillaries. It would therefore follow that ETCO 2 would correlate with DL CO because both are markers of dead space ventilation. In performing the Cox regression analysis, we found that the significant difference in survival between the group of patients with the higher ETCO 2 and the group with lower ETCO 2 was no longer present after adjustment for DL CO in addition to age and sex. This suggests that DL CO and ETCO 2 offer some overlapping information. This observation is further supported by the correlation we found Definition of abbreviations: BMI = body mass index; CCB = calcium channel blocker; CHD = congenital heart disease; CI = cardiac index; CTD = connective tissue disease; DL CO = diffusing capacity of the lung for carbon monoxide; ERA = endothelin receptor antagonist; ETCO 2 = end-tidal carbon dioxide pressure; HPAH = heritable pulmonary arterial hypertension; IPAH = idiopathic pulmonary arterial hypertension; mPAP = mean pulmonary arterial pressure; NYHA = New York Heart Association; PAH = pulmonary arterial hypertension; PCWP = pulmonary capillary wedge pressure; PDE5 = phosphodiesterase type 5 inhibitor; PVR = pulmonary vascular resistance; RAP = right atrial pressure. Combination therapy included ERA 1 prostaglandin, PDE5 1 prostaglandin, ERA 1 PDE5 1 prostaglandin, CCB 1 PDE5, and CCB 1 ERA. Data are presented as mean 6 SD unless otherwise noted. *Unable to calculate P value. † Decrease in ETCO 2 less than or equal to 5 mm Hg (n = 10); increase or decrease in ETCO 2 by less than 5 mm Hg (n = 25); increase in ETCO 2 less than or equal to 5 mm Hg (n = 7). ‡ Decrease in ETCO 2 less than or equal to 5 mm Hg (n = 10); increase or decrease in ETCO 2 by less than 5 mm Hg (n = 26); increase in ETCO 2 less than or equal to 5 mm Hg (n = 8).
x Decrease in ETCO 2 less than or equal to 5 mm Hg (n = 11); increase or decrease in ETCO 2 by less than 5 mm Hg (n = 33); increase in ETCO 2 less than or equal to 5 mm Hg (n = 7).
k Decrease in ETCO 2 less than or equal to 5 mm Hg (n = 11); increase or decrease in ETCO 2 by less than 5 mm Hg (n = 33); increase in ETCO 2 less than or equal to 5 mm Hg (n = 6). ¶ Decrease in ETCO 2 less than or equal to 5 mm Hg (n = 10); increase or decrease in ETCO 2 by less than 5 mm Hg (n = 32); increase in ETCO 2 less than or equal to 5 mm Hg (n = 7). ORIGINAL RESEARCH
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